NMDI14
Based on 16 publication(s) in Google Scholar
NMDI14 is a nonsense mediated RNA decay (NMD) inhibitor. NMDI14 disrupts the SMG7-UPF1 interactions and inhibits NMD.
For research use only. We do not sell to patients.
- Purity: 99.68%
- CAS No.: 307519-88-6
- Formula: C21H25N3O4S
- Molecular Weight:415.51
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) NMDI14
More- Nature. 2023 Jun;618(7966):842-848. [Abstract]
- Nat Commun. 2025 Jul 21;16(1):6695. [Abstract]
- Adv Sci (Weinh). 2025 May;12(18):e2414211. [Abstract]
- Cell Rep Med. 2025 Aug 19;6(8):102244. [Abstract]
- Diabetologia. 2025 Jan;68(1):128-151. [Abstract]
- Anesthesiology. 2023 Jun 1;138(6):634-655. [Abstract]
- Oncogene. 2025 Jul;44(26):2186-2200. [Abstract]
- Cell Rep. 2025 Nov 25;44(11):116544. [Abstract]
- Cell Rep. 2025 Jun 25;44(7):115919. [Abstract]
- Neurosci Bull. 2025 May;41(5):805-820. [Abstract]
- Cell Signal. 2025 Jun:130:111669. [Abstract]
- Eur J Immunol. 2025 Mar;55(3):e2451351. [Abstract]
- eNeuro. 2024 May 24:ENEURO.0034-24.2024. [Abstract]
- SSRN. 2025 Nov 21.
- Genet Med Open. 2025 Nov 17:4:103472. [Abstract]
- bioRxiv. 2025 Oct 15.
Customer Validation & Images
-
RT-PCR
-
WB
-
RT-PCR
-
RT-PCR
-
WB
All DNA/RNA Synthesis Isoforms
More
Biological Activity
NMD[1]
NMDI14 is a nonsense mediated RNA decay (NMD) inhibitor. Treating cells with NMDI14 for 6 hours leads to an increase of PTC 39 β globin to 12%, a relative four-fold increase that, if resulting in biologically active hemoglobin, would be sufficient to ameliorate the clinical symptoms of thalassemia. Three days of treatment with NMDI14 results in no decrease in cell counts, demonstrating that the pharmacological inhibition of NMD can be achieved without subtle changes in proliferation. 941 genes are increased >1.5 fold with NMDI14. The treatment of N417 cells with NMDI14 for 6 hours leads to a steady state expression of p53 similar to that seen in U2OS cells. NMDI14 significantly increases the stability of PTC mutated p53 mRNA in N417 cells, without altering the stability of wild-type p53 in NMDI-treated U2OS cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 307519-88-6
-
Appearance Solid
-
Molecular Weight 415.51
-
Formula C21H25N3O4S
-
Color Light yellow to yellow
-
SMILES
O=C(C1=C(NC(CC2NC3=C(C=C(C)C(C)=C3)NC2=O)=O)SC(C)=C1C)OCC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (16)
-
Journal Impact Factor
-
Most Recent
-
Nature
2023 Jun;618(7966):842-848. PMID: 37258671
NMDI14 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7966):842-848. [Abstract]
NMDI14 (NMD14; 5 µM; 12 h). CFTR mRNA level was normalized to that in untreated cells.
NMDI14 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7966):842-848. [Abstract]
NMDI14 (NMD14; 5 µM; 24 h). Representative immunoblots using monoclonal CFTR-NBD2 antibody in 16HBEgeR1162X/− transfected with sup-tRNA alone using lipofectamine or treated with NMD14.
-
Nat Commun
A UFD1 variant encoding a microprotein modulates UFD1f and IPMK ubiquitination to play pivotal roles in anti-stress responses. [Abstract]2025 Jul 21;16(1):6695. PMID: 40691175
NMDI14 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 21;16(1):6695. [Abstract]
NMDI14 (50 μM; 6 h). RT-qPCR analysis revealing lncRNA GAS5 and UFD1s RNA levels in HEK293T cells under NMDI14 or TG treatments. GAS5 is a known NMD target, and was served as a positive control.
-
Adv Sci (Weinh)
ADAR1-HNRNPL-Mediated CircCANX Decline Promotes Autophagy in Chronic Obstructive Pulmonary Disease. [Abstract]2025 May;12(18):e2414211. PMID: 40091520
NMDI14 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 May;12(18):e2414211. [Abstract]
NMDI14 (5-10 μM; 48 h). P53 expression in cells overexpressing circCANX or its control and treated with NMDI14 based on western blotting.
-
Cell Rep Med
Recreating pathophysiology of CLN2 disease and demonstrating reversion by TPP1 gene therapy in hiPSC-derived retinal organoids and retina-on-chip. [Abstract]2025 Aug 19;6(8):102244. PMID: 40706588 -
Diabetologia
A WFS1 variant disrupting acceptor splice site uncovers the impact of alternative splicing on beta cell apoptosis in a patient with Wolfram syndrome. [Abstract]2025 Jan;68(1):128-151. PMID: 39520565
NMDI14 purchased from MedChemExpress. Usage Cited in: Diabetologia. 2025 Jan;68(1):128-151. [Abstract]
NMDI14 (5 μM; 16 h). RT-qPCR of the four WFS1 isoforms in WFS1 iPSCs after treatment with NMDI-14 or vehicle.
-
Anesthesiology
Phosphorylated upstream frameshift 1-dependent nonsense-mediated μ opioid receptor mRNA decay in the spinal cord contributes to the development of neuropathic allodynia-like behavior in rats. [Abstract]2023 Jun 1;138(6):634-655. PMID: 36867667 -
Oncogene
KPNA2 promotes osteosarcoma progression by regulating the alternative splicing of DDX3X mediated by YBX1. [Abstract]2025 Jul;44(26):2186-2200. PMID: 40216969 -
Cell Rep
Vascular Lamb1 guides the migration of retinal microglial precursors via Itga6-Rac1 signaling. [Abstract]2025 Nov 25;44(11):116544. PMID: 41206867 -
Cell Rep
Inhibiting UPF1 methylation enhances tumor immunotherapy sensitivity by reducing nonsense-mediated mRNA decay. [Abstract]2025 Jun 25;44(7):115919. PMID: 40570371 -
Neurosci Bull
2025 May;41(5):805-820. PMID: 40042769 -
Cell Signal
Two novel SH3TC2 mutations predispose to Charcot-Marie-Tooth disease type 4C by mistargeting away from TFRC. [Abstract]2025 Jun:130:111669. PMID: 39961410 -
Eur J Immunol
Interferons and Cytokines Induce Transcriptional Activation of the Long-Interspersed Element-1 in Myeloid Cells from Autoimmune Patients. [Abstract]2025 Mar;55(3):e2451351. PMID: 40071709 -
eNeuro
2024 May 24:ENEURO.0034-24.2024. PMID: 38789273 -
-
Genet Med Open
CFTR rescue in W1282X cystic fibrosis patient-derived intestinal organoids (PDIOs) mediated by translational readthrough-inducing drugs (TRIDs). [Abstract]2025 Nov 17:4:103472. PMID: 41492359 -
Solvent & Solubility
DMSO : 10 mg/mL (24.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
To assess viability cells are cultured in 6 well dishes and incubated with DMSO, G418, NMDI alone or G418 with NMDI together for the indicated hours. After incubations, cells and media are collected and cells viability is measured. To assess cell proliferation U2OS, Hela and BJ-htert cells are cultured in 6 well plates and, after 24 hrs, treated with NMDI14 for 0, 24, 48 and 72hrs. The cells are collected and viable cells are counted by using the Countess Automated Cell Counter[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Martin L, et al. Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations. Cancer Res. 2014 Jun 1;74(11):3104-1 [Content Brief]
[2]. Aksit MA, Bowling AD, Evans TA, et al. Decreased mRNA and protein stability of W1282X limits response to modulator therapy. J Cyst Fibros. 2019;18(5):606-613. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4067 mL | 12.0334 mL | 24.0668 mL | 60.1670 mL |
| 5 mM | 0.4813 mL | 2.4067 mL | 4.8134 mL | 12.0334 mL | |
| 10 mM | 0.2407 mL | 1.2033 mL | 2.4067 mL | 6.0167 mL | |
| 15 mM | 0.1604 mL | 0.8022 mL | 1.6045 mL | 4.0111 mL | |
| 20 mM | 0.1203 mL | 0.6017 mL | 1.2033 mL | 3.0084 mL |
NMDI14 Related Classifications
HY-111374 Related Classifications
Powered by Bioz